Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-part, Randomised, Placebo-controlled Study to Investigatethe Safety, Tolerability, Pharmacokinetics and Pharmacodynamicsof Single Doses of Inhaled GSK1995057 in Healthy Subjects

Next Previous
Search
Trial Profile

A Two-part, Randomised, Placebo-controlled Study to Investigatethe Safety, Tolerability, Pharmacokinetics and Pharmacodynamicsof Single Doses of Inhaled GSK1995057 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 1995057 (Primary)
  • Indications Acute lung injury; Adult respiratory distress syndrome
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 29 Jan 2018 Dose escalating cohorts in part 1 were conducted at the PAREXEL International Clinical Pharmacology Research Unit, Harrow, UK and part 2 was carried out at Celerion Clinical Pharmacology Unit, Belfast, UK.
    • 29 Jan 2018 Results developing a potent and selective antagonist of TNFR1 (GSK1995057) using a novel domain antibody therapeutic and assessed its efficacy in vitro, in vivo and by taking patient data from this clinical trial, published in the Thorax.
    • 18 Apr 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top